These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25921268)

  • 1. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
    Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
    Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
    Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
    J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.
    Beutel B; Daniliuc CG; Riemann B; Schäfers M; Haufe G
    Bioorg Med Chem; 2016 Feb; 24(4):902-9. PubMed ID: 26810711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.
    Kopka K; Breyholz HJ; Wagner S; Law MP; Riemann B; Schröer S; Trub M; Guilbert B; Levkau B; Schober O; Schäfers M
    Nucl Med Biol; 2004 Feb; 31(2):257-67. PubMed ID: 15013492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo.
    Breyholz HJ; Wagner S; Levkau B; Schober O; Schäfers M; Kopka K
    Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):24-32. PubMed ID: 17372570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
    Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
    Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New in Vivo Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors.
    Beutel B; Song J; Konken CP; Korpos E; Schinor B; Gerwien H; Vidyadharan R; Burmeister M; Li L; Haufe G; Sorokin L
    Bioconjug Chem; 2018 Nov; 29(11):3715-3725. PubMed ID: 30277751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
    Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
    Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.
    Nanjan P; Nambiar J; Nair BG; Banerji A
    Bioorg Med Chem; 2015 Jul; 23(13):3781-7. PubMed ID: 25907368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R
    Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A QSAR study on the inhibition mechanism of matrix metalloproteinase-12 by arylsulfone analogs based on molecular orbital calculations.
    Hitaoka S; Chuman H; Yoshizawa K
    Org Biomol Chem; 2015 Jan; 13(3):793-806. PubMed ID: 25406681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carborane-Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron-Capture Therapy (BNCT).
    Lutz MR; Flieger S; Colorina A; Wozny J; Hosmane NS; Becker DP
    ChemMedChem; 2020 Oct; 15(20):1897-1908. PubMed ID: 32720425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid based hydroxamate and conjugates with biologically active amines: In vitro effect on matrix metalloproteinase-2.
    Ponedel'kina IY; Gaskarova AR; Khaybrakhmanova EA; Lukina ES; Odinokov VN
    Carbohydr Polym; 2016 Jun; 144():17-24. PubMed ID: 27083788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
    Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.
    Hugenberg V; Breyholz HJ; Riemann B; Hermann S; Schober O; Schäfers M; Gangadharmath U; Mocharla V; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
    J Med Chem; 2012 May; 55(10):4714-27. PubMed ID: 22540974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.